The effects of sirolimus on wound healing in dermatologic surgery

Dermatologic Surgery

Volumn 34, Issue 2, 2008, Pages 216-223

  Brewer, Jerry D ^a   Otley, Clark C ^a   Christenson, Leslie J ^a   Phillips, P Kim ^a   Roenigk, Randall K ^a   Weaver, Amy L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROL GROUP; CONTROLLED STUDY; DATA BASE; DRUG EFFECT; FEMALE; GRAFT RECIPIENT; HUMAN; INTERVIEW; MALE; MEDICAL RECORD; ORGAN TRANSPLANTATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN SURGERY; STATISTICAL SIGNIFICANCE; TELEPHONE; WOUND HEALING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PATIENT SATISFACTION; POSTOPERATIVE COMPLICATIONS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SIROLIMUS; SKIN DISEASES; TREATMENT OUTCOME; WOUND HEALING;

EID: 38349138918     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2007.34040.x     Document Type: Article

References (32)

1. Kahan BD, The Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000 356 : 194 202.
2. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998 31 : 335 40.
3. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transplant 2001 7 : 473 84.
4. Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003 76 : 375 82.
5. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 2000 69 : 2085 90.
6. Troppmann C, Pierce JL, Gandhi MM, et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation 2003 76 : 426 9.
7. Valente JF, Hricik D, Weigel K, et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003 3 : 1128 34.
8. Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002 74 : 804 8.
9. Watson CJ, Friend PJ, Jamieson NV, et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999 67 : 505 9.
10. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004 77 : 1555 61.
11. Humar R, Kiefer FN, Berns H, et al. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002 16 : 771 80.
12. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 2002 3 : 295 304.
13. Marsland AM, Griffiths CE. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002 12 : 618 22.
14. Euvrard S, Ulrich C, Lefrancois N. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 2004 30 : 628 33.
15. Yakupoglu YK, Kahan BD. Sirolimus: a current perspective. Exp Clin Transplant 2003 1 : 8 18.
16. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005 80 : 883 9.
17. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004 18 : 446 9.
18. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002 8 : 128 35.
19. Cotterell AH, Fisher RA, King AL, et al. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002 16 (Suppl) : 49 51.
20. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003 35 (Suppl) : 52S 7S.
21. Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000 14 : 97 109.
22. Brattstrom C, Wilczek HE, Tyden G, et al. Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplant Proc 1998 30 : 3950 1.
23. Brattstrom C, Wilczek H, Tyden G, et al. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998 65 : 1272 4.
24. Mohaupt MG, Vogt B, Frey FJ. Sirolimus-associated eyelid edema in kidney transplant recipients. Transplantation 2001 72 : 162 4.
25. Aboujaoude WJ, Milgrom ML, Nayee LH, et al. Lymphedema associated with sirolimus in renal transplant recipients [Abstract #1311]. Am J Transplant 2003 3 (Suppl) : 488.
26. Wadei H, Gruber S, Garnick J, et al. Sirolimus (SRL)-induced angioedema: report of two cases [Abstract 1310]. Am J Transplant 2003 3 (Suppl) : 488.
27. Migita K, Eguchi K, Ichinose Y, et al. Effects of rapamycin on apoptosis of rheumatoid synovial cells. Clin Exp Immunol 1997 108 : 199 203.
28. Groth CG, Backman L, Morales JM, et al, Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999 67 : 1036 42.
29. Guilbeau JM. Delayed wound healing with sirolimus after liver transplant. Ann Pharmacother 2002 36 : 1391 5.
30. Kaplan MJ, Ellis CN, Bata-Csorgo Z, et al. Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes. Arch Dermatol 1999 135 : 553 7.
31. Kahn D, Spearman W, Mall A, et al. Rapamycin impairs the healing of the ureteric anastomosis [abstract]. Transplantation 2004 78 (Suppl) : 259.
32. King-Biggs MB, Dunitz JM, Park SJ, et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003 75 : 1437 43.